March 30 (Reuters) – Merck’s oral drug reduced bad cholesterol by 64.6% in a late-stage trial, it said on Monday, as the company looks for its next blockbuster candidate.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shreya Biswas)
Brought to you by www.srnnews.com